apparent diffusion coefficient adc maps (Bruker Corporation)
Bruker Corporation is a verified supplier 
Bruker Corporation manufactures this product 
97
Structured Review
Bruker Corporation
apparent diffusion coefficient adc maps
Apparent Diffusion Coefficient Adc Maps, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 3085 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apparent-diffusion-coefficient/Diffusion/bio_rxiv__2025__10__22__684053-75-0-10
Average 97 stars, based on 3085 article reviews
Apparent Diffusion Coefficient Adc Maps, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 3085 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apparent-diffusion-coefficient/Diffusion/bio_rxiv__2025__10__22__684053-75-0-10
Average 97 stars, based on 3085 article reviews
apparent diffusion coefficient adc maps - by Bioz Stars,
2026-11
97/100 stars
Images
1) Product Images from "Multimodal Characterization and Evolution of Malonate-induced Stroke Model: Advanced MRI, Histology-Molecular Profiling"
Article Title: Multimodal Characterization and Evolution of Malonate-induced Stroke Model: Advanced MRI, Histology-Molecular Profiling
Journal: bioRxiv
doi: 10.1101/2025.10.22.684053
Figure Legend Snippet: A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion coefficient (ADC) observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
Techniques Used: Diffusion-based Assay, Injection, MANN-WHITNEY
Related Articles
Diffusion-based Assay:Article Title: Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti‐ PD ‐1 Immunotherapy in Pancreatic Ductal Adenocarcinoma Article Snippet: .. For DWI, the apparent Article Title: Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities Article Snippet: E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B.. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumorpromoting aspects of the tumor microenvironment (TME) by suppressing cancer-associated fibroblasts (CAF) and promoting remodeling of tumor vasculature.. Here, we demonstrate TME amelioration by E7130 using multi-imaging modalities, including multiplexed mass cytometry [cytometry by time-of-flight (CyTOF)] analysis, multiplex IHC analysis, and MRI. Article Title: Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus. Article Snippet: .. Article Title: Multimodal Characterization and Evolution of Malonate-induced Stroke Model: Advanced MRI, Histology-Molecular Profiling Article Snippet: The MRI data were reconstructed and analyzed using MP3 software developed in MATLAB (MathWorks, USA). .. Article Title: Intratumoral heterogeneity after targeted therapy in murine cancer models with differing degrees of malignancy. Article Snippet: .. The Article Title: Tauroursodeoxycholic acid reduces brain lesion volume and cortical edema in a rat model of Traumatic brain injury. Article Snippet: Background: Traumatic brain injury (TBI) continues to be a major cause of death and disability worldwide.. Effective treatment options are limited, and randomized clinical data has been futile.. Objective: In this study, we assessed the efficacy of tauroursodeoxycholic acid (TUDCA) in treating TBI using a controlled cortical impact injury model in male Wistar rats. Article Title: Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. Article Snippet: .. ADC: Software:Article Title: Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti‐ PD ‐1 Immunotherapy in Pancreatic Ductal Adenocarcinoma Article Snippet: .. For DWI, the apparent Article Title: Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities Article Snippet: E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B.. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumorpromoting aspects of the tumor microenvironment (TME) by suppressing cancer-associated fibroblasts (CAF) and promoting remodeling of tumor vasculature.. Here, we demonstrate TME amelioration by E7130 using multi-imaging modalities, including multiplexed mass cytometry [cytometry by time-of-flight (CyTOF)] analysis, multiplex IHC analysis, and MRI. Article Title: Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus. Article Snippet: .. Article Title: Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus Article Snippet: .. Generated:Article Title: Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities Article Snippet: E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B.. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumorpromoting aspects of the tumor microenvironment (TME) by suppressing cancer-associated fibroblasts (CAF) and promoting remodeling of tumor vasculature.. Here, we demonstrate TME amelioration by E7130 using multi-imaging modalities, including multiplexed mass cytometry [cytometry by time-of-flight (CyTOF)] analysis, multiplex IHC analysis, and MRI. Article Title: Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus. Article Snippet: .. Article Title: Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus Article Snippet: .. Article Title: Tauroursodeoxycholic acid reduces brain lesion volume and cortical edema in a rat model of Traumatic brain injury. Article Snippet: Background: Traumatic brain injury (TBI) continues to be a major cause of death and disability worldwide.. Effective treatment options are limited, and randomized clinical data has been futile.. Objective: In this study, we assessed the efficacy of tauroursodeoxycholic acid (TUDCA) in treating TBI using a controlled cortical impact injury model in male Wistar rats. Sequencing:Article Title: Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities Article Snippet: E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B.. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumorpromoting aspects of the tumor microenvironment (TME) by suppressing cancer-associated fibroblasts (CAF) and promoting remodeling of tumor vasculature.. Here, we demonstrate TME amelioration by E7130 using multi-imaging modalities, including multiplexed mass cytometry [cytometry by time-of-flight (CyTOF)] analysis, multiplex IHC analysis, and MRI. |
